Stephen C. Harris



Curriculum VitaeAlexander I. SankinHome Address: 400 E. 84th St Apt 12A NY, NY 10028Phone: 267-980-4606Email: alexsankin@Citizenship: United StatesBirthdate: 1/19/1982EDUCATION Bachelor of Arts (B.A.) in Biochemistry with a Minor in Music. University of Pennsylvania, Philadelphia, PA. 2004Master of Science (M.S.) in Chemistry. University of Pennsylvania, Philadelphia, PA. 2004Doctor of Medicine (M.D.) with Honors in Cell Biology. New York University School of Medicine, New York, NY. 2008PROFESSIONAL EXPERIENCE General Surgery Intern. SUNY Downstate Medical Center Department of Surgery, Brooklyn, NY. 2008 - 2009Urologic Surgery Resident. SUNY Downstate Medical Center Department of Urology, Brooklyn, NY. 2009 - 2013Director of Urologic Didactic Series and Resident Education. SUNY Downstate Medical Center Department of Urology, Brooklyn, NY. 2009 – 2013Urologic Oncology Fellow. Memorial Sloan-Kettering Cancer Center Department of Urology, New York, NY. 2013 – 2015Director of Urologic Didactic Series. Memorial Sloan-Kettering Cancer Center Department of Urology, New York, NY. 2014 – 2015Assistant Professor and Attending. Montefiore Medical Center and Albert Einstein College of Medicine Department of Urology, Bronx, NY. 2015 – PresentPROFESSIONAL MEMBERSHIPS Member, American Medical Association. 2004 – PresentChair of Pharmacy and Volunteer, NYC Free Clinic. 2004 – 2006Mentor, Brothers and Sisters in Science. 2004 – 2005President, Medical Physics Club. 2005 – 2006Treasurer, Musical Therapy Club. 2005 – 2006Member, American Urological Association. 2008 – PresentAssociate Member, Society of Urological Oncology, 2015 – Present HONORS AND AWARDS Vagelos Scholar in Molecular Life Sciences. University of Pennsylvania, Philadelphia, PA. 2004Magna Cum Laude. University of Pennsylvania, Philadelphia, PA. 2004.Medical Degree conferred with Honors in Cell Biology. New York University School of Medicine, New York, NY. 2008.Samuel and Edgar M. Soifer Award for Excellence in Urology. New York University School of Medicine, New York, NY. 2008.Best Poster in Session Award at 23rd European Association of Urology Annual Meeting, Milan Italy, 2008. Do biopsy characteristics predict unilateral prostate cancer on radical prostatectomy?Outstanding Performance Award in Pre-Urology Year. SUNY Downstate Medical Center Department of Surgery, Brooklyn, NY. 2009Highest Score Award in AUA Annual Inservice Exam. SUNY Downstate Medical Center Department of Urology, Brooklyn, NY. 2010Third Prize Award at Murry Friedman Resident Competition, New York, NY, 2011. Evaluating parameters affecting renal function following partial nephrectomy using nuclear renal scintigraphy and eGFR. Highest Score Award in AUA Annual Inservice Exam. SUNY Downstate Medical Center Department of Urology, Brooklyn, NY. 2012Chief Residents’ Debate Participant at New York Academy of Medicine, New York, NY. 2013NIH T32 Training Grant Award at Memorial Sloan-Kettering Cancer Center, New York, NY. 2013Stephen P. Hansen Family Fund Fellowship in Kidney Cancer Award at Memorial Sloan-Kettering Cancer Center, New York, NY. 2013INSTITUTIONAL/HOSPITAL AFFILIATION____________________________________Primary Hospital Affiliation: Montefiore Medical CenterEMPLOYMENT STATUS___________________________________________________Name of Current Employer: Montefiore Medical CenterEmployment Status: Full-timeCURRENT AND PAST INSTITUTIONAL RESPONSIBILITIES AND PERCENT EFFORT1, Teaching/Mentoring2008-Present. Teaching of medical students and residents in outpatient clinic and operating room. 5 hours/week.2. Clinical care2008-Present. See patients in clinic 2.5 days/week. Operating room 2 days/week.3. Administrative duties2009-2013. Director of Urologic Didactic Lectures and Resident Education2013-2014 Administrative Fellow for Kidney Cancer Working Group2014-2015 Director of Urologic Oncology Didactic Lectures and Fellow Education4. ResearchDepartment of Pharmacology, University of Pennsylvania, 2001 – 2002. Studied Vancomycin binding properties under Dr. Paul Axelsen (techniques included FRET, molecular dynamics simulations, computer modeling)Department of Microbiology, University of Pennsylvania, 2002 – 2004. Studied virus/host interactions of MMTV on transferrin receptor under Dr. Susan Ross (techniques included gene mutagenesis, PCR, DNA purification)Department of Cell Biology, New York University, 2004. Studied integrin activation by TGF-Beta under Dr. John Munger (techniques included plasmid design, RNAi, tissue culture)Hospital for Joint Disease, New York, 2005 Studied the effect of estrogen on osteoarthritis under Dr. Paul DiCesare (techniques included cartilage harvesting, RNA extraction, Real Time PCR)Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, 2013-2014. Studied RCC genetic heterogeneity and its impact on biomarker development under Dr. James Hsieh (techniques included mutation profiling via next generation sequencing) Current Percent Effort (%) Teaching/Mentoring 10Clinical Care 75Administration 5Research 10BIBLIOGRAPHY ARTICLESClark TW, Sankin A, Becske T, Nelson PK, Fox M. Stent-assisted Gugliemi detachable coil repair of wide-necked renal artery aneurysm using 3-D angiography. Vasc Endovascular Surg 2008 Jan; 41(6):528-32Tareen B, Sankin A, Godoy G, Temkin S, Lepor H, Taneja SS. Appropriate candidates for hemiablative focal therapy are infrequently encountered among men selected for radical prostatectomy in contemporary cohort. Urology. 2009 Feb;73(2):351-4Tareen B, Godoy G, Sankin A, Temkin S, Lepor H, Taneja SS. Laterality alone should not drive selection of candidates for hemi-ablative focal therapy. J Urol. 2009 Mar;181(3):1082-9Tareen B, Godoy G, Sankin A, Temkin S, Lepor H, Taneja SS. Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer? BJU Int. 2009 Jul;104(2):195-9Marien T, Sankin A, Lepor H. Factors predicting preservation of erectile function in men undergoing open radical retropubic prostatectomy. J Urol. 2009 Apr;181(4):1817-22Sankin A, Tareen B, Lepor H. Side-specific factors associated with extracapsular extension and seminal vesicular invasion in men undergoing open radical retropubic prostatectomy. Prostate Cancer Prostatic Dis. 2009;12(2):204-8Mufarrij P, Sankin A, Godoy G, Lepor H. Pathologic outcomes of candidates for active surveillance undergoing radical prostatectomy. Urology. 2010 Sep;76(3):689-92Sankin A, Cohen J, Wang H, Macchia RJ, Karanikolas N. Rate of renal cell carcinoma subtypes in different races. Int Braz J Urol. 2011 Feb;37(1):29-32Sankin A, Sfakianos J, Schiff J, Sjoberg D, Coleman J. Assessing renal function following partial nephrectomy using renal nuclear scintigraphy and eGFR. Urology. 2012 Aug;80(2):343-6Ghavamian R, Hakimi AA, Williams SK, Kim PH, Chen L, Sfakianos JP, Keren-Paz GE, Sankin A, Ginzburg N, Coleman JA. Factors affecting proportional glomerular filtration rate following minimally invasive partial nephrectomy. J Endourology 2013 Nov;27(11):1371-5Sankin A, Hakimi AA, Mikkilineni N, Ostrovnaya I, Silk MT, Liang Y, Mano R, Chevinsky M, Motzer RJ, Solomon SB, Cheng EH, Durack JC, Coleman JA, Russo P, Hsieh JJ. The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling. Cancer Medicine 2014 Dec;3(6):1485-92Mano R, Vertosick E, Sankin A, Chevinsky M, Larish Y, Jakubowski CD, Hotker AM, Sjoberg D, Akin O, Russo P. The clinical significance of indeterminate pulmonary nodules in patients with renal cell carcinoma. J Urol 2014 Mar;193(3):776-82Chevinsky M, Imnadze M, Sankin A, Winer A, Mano R, Jakubowski C, Mashni J, Sjoberg DD, Chen YB, Tickoo SK, Reuter VE, Hakimi AA, Russo P. Pathologic stage T3a significantly increases disease recurrence across all tumor sizes in renal cell carcinoma. J Urol 2015 Aug;194(2):310-5Hakimi AA, Tickoo S, Jacobsen A, Sarungbam J, Sfakianos J, Sato Y, Morikawa T, Kume H, Fukayama M, Homma Y, Chen YB, Sankin A, Mano R, Coleman JA, Russo P, Ogawa S, Sander C, Hsieh JJ, Reuter VE. TCEB1-mutated renal cell carcinoma: a distinct genomic and morphologic subtype. Mod Pathol 2015 June;28(6):845-53Sankin A, Hakimi AA, Hsieh JJ, Molina AM. Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies. Front Oncol 2015 Apr 8;5:67Hakimi AA, Ostrovnaya I, Jacobsen A, Susztak K, Coleman JA, Russo P, Winer AG, Mano R, Sankin A, Motzer RJ, Voss MH, Offit K, Purdue M, Pomerantz M, Freedman M, Choueiri TK, Hsieh JJ, Klein RJ. Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma. Cancer 2016 Feb 1;122(3):402-10Sankin A. Discovering biomarkers within the genomic landscape of renal cell carcinoma. J Kidney 2016 (Epub ahead of print)Sankin A, Tin A, Mano R, Chevinsky M, Jakubowski C, Cha E, Yee A, Friedman F, Sjoberg D, Ehdaie B, Coleman J. Impact of ureteroscopy prior to nephroureterectomy for upper tract urothelial carcinoma on oncologic outcomes. Urology 2016 (Epub ahead of print)POSTERS AND PRESENTATIONSRoss SR, Schofield J, Sankin A, Burzyn D, Piazzon I. MMTV and its interaction with transferrin receptor. 15th International Workshop on Retroviral Pathogenesis, Glasgow, UK, 2003Frenkel SR, Liu C, Patel V, Sankin A, Leslie M, Siu S, DiCesare PE. Estrogen’s role in osteoarthritis: chondroprotective or chondrodestructive? American Academy of Orthopedic Surgeons Annual Meeting, San Diego, CA, 2007Tareen B, Sankin A, Godoy G, Temkin S, Lepor H, Taneja SS. Do biopsy characteristics predict unilateral prostate cancer on radical prostatectomy? European Association of Urology Annual Meeting, Milan, Italy, 2008Tareen B, Sankin A, Godoy G, Temkin S, Lepor H, Taneja SS. Comparison of pathologic and oncologic outcomes of radical retropubic prostatectomy among men with unilateral vs bilateral prostate cancer: implications for focal therapy. European Association of Urology Annual Meeting, Milan, Italy, 2008Sankin A, Tareen B, Lepor H. Preoperative risk factors predicting side specific extra-capsular extension in prostate cancer. American Urological Association Annual Meeting, Orlando, FL, 2008Marien T, Sankin A, Tareen B, Lepor H. Factors predicting preservation of potency in men undergoing radical retropubic prostatectomy. American Urological Association Annual Meeting, Orlando, FL, 2008Tareen B, Sankin A, Godoy G, Temkin S, Lepor H, Taneja SS. Do candidates for focal therapy exist among a contemporary cohort of radical prostatectomy patients? American Urological Association Annual Meeting, Orlando, FL, 2008Mufarrij P, Sankin A, Godoy G, Lepor H. Pathologic outcomes of candidates for active surveillance undergoing radical prostatectomy. American Urological Association Annual Meeting, Chicago, IL, 2009Sankin A. Does ethnicity influence renal cell carcinoma subtype? Valentine Essay Meeting, New York Section of American Urological Association, 2010Sankin A. Evaluating parameters affecting renal function following partial nephrectomy using nuclear renal scintigraphy and eGFR. Valentine Essay Meeting, New York Section of American Urological Association, 2011Sprenkle P, Sankin A, Savage C, Musser J, Touijer K, Russo P, Coleman J. Outcomes following renal surgery in high-risk patients: a non-randomized comparison of open and minimally invasive surgical approaches. American Urological Association Annual Meeting, Washington, DC, 2011Sankin A, Hakimi AA, Mano R, Mikkilineni N, Chevinsky M, Russo P, Coleman J, Offit K, Hsieh J, Klein R. Clinicopathological Presentation of Clear Cell Renal Cell Carcinoma in Patients with a Site Specific Single Nucleotide Polymorphism in the MET Oncogene. Society of Urologic Oncology Annual Meeting, Bethesda, MD 2013Sankin A, Kent M, Sjoberg D, Scardino PT. Does tumor grade affect the relationship between preoperative prostate specific antigen (PSA) and biochemical recurrence (BCR)? Genitourinary Cancer Symposium, San Francisco, CA 2014Mano R, Vertosick E, Sankin A, Chevinsky M, Larish Y, Jakubowski C, Hotker A, Hakimi AA, Sjoberg D, Akin O, Russo P. The clinical significance of indeterminate pulmonary nodules in renal cell carcinoma. American Urological Association Annual Meeting, Orlando, FL, 2014Sankin A, Hakimi AA, Mikkilineni N, Ostrovnaya I, Silk MT, Liang Y, Mano R, Chevinsky M, Motzer RJ, Solomon SB, Cheng EH, Durack JC, Coleman JA, Russo P, Hsieh JJ. Regional genetic variability detected with renal tumor biopsies: implications in biomarker development. American Urological Association Annual Meeting, Orlando, FL, 2014Hakimi AA, Ostrovnaya I, Jacobsen A, Coleman JA, Russo P, Mano R, Sankin A, Motzer RJ, Purdue M, Pomerantz M, Freedman M, Choueiri T, Hsieh HH, Klein R. Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma. American Urological Association Annual Meeting, Orlando, FL, 2014Chevinsky M, Imnadze M, Sankin A, Mano R, Jakubowski C, Hakimi AA, Mashni J, Sjoberg D, Reuter V, Chen Y, Russo P. Pathologic stage T3a significantly increases disease recurrence across all tumor sizes in renal cell carcinoma. American Urological Association Annual Meeting, Orlando, FL, 2014Sankin A, Kent M, Sjoberg D, Scardino PT. Does tumor grade affect the relationship between preoperative prostate specific antigen (PSA) and biochemical recurrence (BCR)? American Urological Association Annual Meeting, Orlando, FL, 2014Sankin A, Tin AL, Mano R, Chevinsky M, Jakubowski C, Sfakianos J, Cha E, Yee A, Friedman F, Sjoberg D, Ehdaie B, Coleman JA. Impact of ureteroscopy prior to nephroureterectomy for upper tract urothelial carcinoma on oncologic outcomes. Society of Urologic Oncology Annual Meeting, Bethesda, MD, 2014Murray K, Winer A,Bagrodia A, Kaffenberger S, Vacchio M, Sankin A, Cha E, Benfante N, Dalbagni G, Vetter J, Coleman J, Strope S. Endoscopic management for upper tract urothelial cancer compared to immediate nephroureterectomy: survival outcomes in SEER database and cancer center cohort. American Urological Association Annual Meeting, New Orleans, LA, 2015. Winer A, Vacchio M, Murray K, Kaffenberger S, Bagrodia A, Cha E, Sankin A, Sfakianos J, Dalbagni G, Coleman J. Histological Variants of Upper Urinary Tract Urothelial Carcinoma: The 18-Year MSKCC Experience. American Urological Association Annual Meeting, New Orleans, LA, 2015. Sankin A, Tin A, Mano R, Chevinsky M, Jakubowski C, Cha E, Yee A, Friedman F, Sjoberg D, Ehdaie B, Coleman J. Impact of ureteroscopy prior to nephroureterectomy for upper tract urothelial carcinoma on oncologic outcomes. American Urological Association Annual Meeting, New Orleans, LA, 2015. Sankin A, Winer A, Wei E, Chevinsky M, Silk T, Jakubowski C, Jacques F, Durack J, Coleman J, Berger M, Russo P, Hsieh J, Hakimi A. Overcoming the obstacle of intratumor heterogeneity in RCC through ultra deep sequencing of pooled regional tumor DNA. American Urological Association Annual Meeting, New Orleans, LA, 2015. Mano R, Lee W, Sankin A, Chevinsky A, Wang A, Djesevic A, Motzer R, Cheng E, Russo P, Oschwald D, Bhanot U, Tickoo S, Hakimi A, Hsieh J. Molecular Characterization of Sarcomatoid Clear Cell Renal Cell Carcinoma. American Urological Association Annual Meeting, New Orleans, LA, 2015. Sankin A, Tin A, Mano R, Chevinsky M, Jakubowski C, Cha E, Yee A, Friedman F, Sjoberg D, Ehdaie B, Coleman J. Impact of ureteroscopy prior to nephroureterectomy for upper tract urothelial carcinoma on oncologic outcomes. International Bladder Cancer Network Annual Meeting, Athens, Greece, 2015Sankin A, Gartrell B, Cumberbatch K, Huang H, Stern JM, Schoenberg M, Zang X. A new target for immune checkpoint inhibition in urothelial carcinoma. American Urological Association Annual Meeting, San Diego, CA, 2016. Date: 6/3/2016Signature: _________ALEXANDER SANKIN________ ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download